PA
BHVN

Parallel Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Parallel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43
Closed -$7K – 3637
2022
Q3 		$7K Buy
43
+13
+43% +$1.93K ﹤0.01% 2180
2022
Q2 		$4K Sell
30
-1
-3% -$128 ﹤0.01% 2407
2022
Q1 		$4K Buy
31
+6
+24% +$748 ﹤0.01% 2431
2021
Q4 		$3K Sell
25
-109
-81% -$13.9K ﹤0.01% 2643
2021
Q3 		$19K Buy
134
+116
+644% +$14.5K ﹤0.01% 1780
2021
Q2 		$2K Hold
18
– – ﹤0.01% 2669
2021
Q1 		$1K Hold
18
– – ﹤0.01% 2769
2020
Q4 		$2K Hold
18
– – ﹤0.01% 2385
2020
Q3 		$1K Hold
18
– – ﹤0.01% 2541
2020
Q2 		$1K Buy
+18
New +$958 ﹤0.01% 2417

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Parallel Advisors's BHVN Position: Q4 2022 in Review

Parallel Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 43 shares — an estimated $7K sold.

Parallel Advisors first reported a position in BHVN in Q2 2020 and held it in 10 quarters. The position peaked at $19K in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Parallel Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 43 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $7K.
  • Parallel Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 10 quarters.
  • Parallel Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $19K in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.